As part of scientific exchange, Novartis is providing the most recent abstract(s) and/or presentation(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Before prescribing any product, always refer to the Prescribing Information (PI), Summary of Product Characteristics (SmPC), or product information as appropriate in your country. Information is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.
This is for your background and educational purposes only and may not be altered or further disseminated in any fashion.
For distribution in response to an unsolicited request for medical information subject to local approval.
Content to be used in accordance with local CPO guidelines
Trial in Progress: NETTER-3: A Phase III Study of [177Lu]Lu-DOTA-TATE in Patients With Newly Diagnosed, Grade 1 and Grade 2 (Ki-67 <10%) Advanced Gastroenteropancreatic Neuroendocrine Tumors and High Disease Burden
Simron Singh, Jaume Capdevila, Thorvardur R. Halfdanarson, Daniel Halperin, Ken Herrmann, Marianne E. Pavel, Jiapan Xu, Dhrubajyoti Pathak, Pamela L. Kunz
Poster Presentation #1735TiP
Hall 25 | Monday, 20, 2025 | 09:00-17:00 CEST (Poster)